Prenatal treprostinil improves pulmonary arteriolar hypermuscularization in the rabbit model of congenital diaphragmatic hernia

Felix R. De Bie, Yannick Regin, Antoine Dubois, Marianna Scuglia, Tomohiro Arai, Ewout Muylle, David Basurto, Marius Regin, Siska Croubels, Marc Cherlet, Emily A. Partridge, Karel Allegaert, Francesca M. Russo, Jan A. Deprest

A R T I C L E  I N F O

Keywords:
Foetal therapy – pulmonary hypertension – congenital diaphragmatic hernia - treprostinil

A B S T R A C T

Congenital diaphragmatic hernia (CDH) is a congenital malformation characterized by pulmonary hypoplasia, pulmonary hypertension, and cardiac dysfunction. Pulmonary hypertension represents the major cause of neonatal mortality and morbidity. Prenatal diagnosis allows assessment of severity and selection of foetal surgery candidates. We have shown that treprostinil, a prostacyclin analogue with an anti-remodelling effect, attenuates the relative hypermuscularization of the pulmonary vasculature in rats with nitrofen-induced CDH. Here we confirm these observations in a large animal model of surgically-created CDH. In the rabbit model, subcutaneous maternal administration of treprostinil at 150 ng/kg/min consistently reached target foetal concentrations without demonstrable detrimental foetal or maternal adverse effects. In pups with CDH, prenatal treprostinil reduced pulmonary arteriolar proportional medial wall thickness and downregulated inflammation and myogenesis pathways. No effect on alveolar morphometry or lung mechanics was observed. These findings provide further support towards clinical translation of prenatal treprostinil for CDH.

Research in context

Evidence before this study
Persistent pulmonary hypertension causes significant mortality and morbidity in infants with congenital diaphragmatic hernia (CDH). Foetal endoluminal tracheal occlusion is currently the only validated foetal therapy for CDH, however is associated with higher rates of preterm delivery and its effect on pulmonary vascular development has not been fully elucidated. We therefore investigated a prenatal, pharmacologic, non-invasive therapy specifically targeting pulmonary vascular development in CDH. Treprostinil has demonstrated antiremodeling effects on pulmonary vascular smooth muscles cells demonstrated in vitro, and in a nitrofen rat model of CDH prenatal treprostinil has been demonstrated to reduce the pulmonary hypertensive phenotype.

Added value of this study
We herein demonstrate that (1) treprostinil’s antiremodeling receptors are expressed at relevant foetal age, (2) treprostinil administration during the pseudo-glandular lung development phase is well tolerated by the mother and the foetus, and (3) prenatal maternal treprostinil administration reduces the pulmonary arteriolar hypermuscularization in foetal rabbit pups with surgically-induced CDH, downregulates inflammation and myogenesis pathways, improving the pulmonary hypertensive phenotype. This study corroborates previous findings in the nitrofen rat model, now in a higher species, which is closer to humans in terms of pulmonary development, providing

© 2023 Published by Elsevier Masson SAS. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
essential information on the safety and efficacy of treprostinil, and clearing the way towards clinical translation.

Implications of all the available evidence

This study provides evidence of safety and efficacy of prenatal treprostinil treatment in CDH in a second, higher animal model of CDH, paving the way for clinical investigation of the potential of prenatal treprostinil administration to improve prenatal pulmonary vascular development in CDH.

1. Introduction

Congenital diaphragmatic hernia (CDH) is a rare congenital malformation (2.3/10,000 live births) characterized by a diaphragmatic defect allowing herniation of abdominal viscera into the chest, resulting in compression of the developing lungs and heart[1]. The pathophysiology of CDH is characterized by airway hypoplasia, pulmonary vascular remodelling, and cardiac dysfunction. After birth this results in impaired gas exchange, pulmonary hypertension (PH) and ventricular dysfunction[2–4]. Despite improvements in neonatal intensive care, refractory PH accounts for most CDH-related mortality and morbidity[4]. CDH can be diagnosed prior to birth, and the severity of pulmonary hypoplasia assessed. Adverse structural pulmonary changes in CDH have been described in a larger animal model. In this study, we aimed to assess tolerability and effectiveness of prenatal pulmonary hypoplasia a promising therapeutic strategy. Clinically, Fetoscopic Endoluminal Tracheal Occlusion (FETO) has been demonstrated to improve survival in selected foetuses[5,6]. However, experimental studies have demonstrated that FETO mainly addresses airway hypoplasia[7–9]. Prenatal therapy to reverse abnormal vascular development would represent a breakthrough in CDH treatment. Ideally, such prenatal intervention would be non-invasive, without significant maternal and foetal adverse effects[10]. Treprostinil is a non-teratogenic prostacyclin-analogue used to treat PH in neonates with CDH[11–14]. In vitro, treprostinil reduces the proliferation of pulmonary arteriolar smooth muscle cells[15–17]. In vivo, we previously demonstrated that in rat pups with nitrogen-induced CDH, placental treprostinil reduces the proportional mediol wall thickness characteristic of pulmonary arterioles in CDH-PH[2]. In anticipation of clinical translation, the safety and efficacy of treprostinil must be validated in a larger animal model. In this study, we aimed to assess tolerability and effectiveness of prenatal treprostinil in rabbit pups with surgically-induced CDH.

2. Material and methods

2.1. Ethics

This study was approved by the Ethics Committee for Animal Experimentation of the KU Leuven of the Faculty of Medicine (P079/2021) and followed the ARRIVE 2.0 guidelines for reporting on animal research[18].

2.2. Animals

Time-dated, drug-naive pregnant rabbits (hybrid of New Zealand and Flemish Giant rabbits) were obtained from a registered breeder and housed in individual cages at 21 °C and 42% humidity, with a 12-hour day/night cycle and free access to water and food.

2.3. Treprostinil administration

To ensure continuous, subcutaneous administration of treprostinil (10 mg/mL Remodulin®, United Therapeutics Corporation, Silver Springs, MD, USA) programmable iPRECIO drug infusion pumps (SMP-200, Primetech Corporation, Tokyo, Japan) were used. Weight-adjusted treprostinil doses were prepared, using the formulas in the product data sheet[13]. Under sterile conditions, treprostinil was dissolved in phosphate-buffered saline (PBS) 1X (Gibco, Thermo Fisher Scientific, Waltham, MA, USA) and loaded in the pump. In CTRL rabbits, a pump delivering NaCl 0.9% was implanted. Pumps were programmed to start drug delivery ten hours after surgical implantation, and 24 h when combined with CDH creation, to allow for post-anaesthesia recovery. Pumps were retrieved at the end of the experiment, thoroughly washed, programmed to pump sterile PBS through the catheter during 24 h, sterilized (2% glutaraldehyde for 12 h) and stored in a Penicillin/Streptomycin (100 U/mL, 100 µg/mL) solution until next use, as previously described[19]. Pumps were not re-used more than three times.

2.4. Pump implantation procedure

Pumps were implanted subcutaneously in the maternal neck scruff under general inhalation anesthesia (4% Sevoflurane, 2 L/min O₂). Since treprostinil can cause local erythema, care was taken to make a large subcutaneous pocket and to turn the tip of the drug delivery catheter away from the incision, prior to closure with intradermal resorbable sutures (Monocryl 3–0, Ethicon, Raritan, NJ, USA). In does undergoing surgical creation of CDH, pumps were implanted at the end of the procedure.

2.5. Treprostinil plasma concentration analysis

Maternal blood was sampled via cardiac puncture immediately prior to euthanasia, and fetal blood via decapitation. Blood samples were kept in EDTA tubes and centrifuged at 2000 g, 4 °C for 15 min. The supernatant plasma was collected and stored at – 80 °C for concentration analysis with validated ultra-high performance liquid chromatography-tandem mass-spectrometry (UHPLC-MS) analysis in two batches by the Laboratory of Pharmacology and Toxicology (Good Laboratory Practice compliant laboratory) at the Department Pathobiology, Pharmacology and Zoological Medicine at the Faculty of Veterinary Medicine of Ghent University in Merelbeke, Belgium. The methodology for the UHPLC-MS analysis is detailed in the supporting information (SI1). The transplacental transfer ratio was calculated as follows: [(average fetal concentration/average maternal concentration) x 100]%[2].

2.6. Maternal tolerance outcomes

From GD22 onwards, does were monitored daily for food intake (maximum 130 g/day), heart rate using electrocardiography (average of three sequential measurements), maternal weight and relative weight gain per pup calculated as [body weight after therapy – body weight before therapy]/size of the litter], pain using the validated rabbit grimace score[20] and behavior using a behavioral assessment scale (Table S1)[20–22]. Does were also inspected for treprostinil-specific adverse effects such as pump-site erythema, induration and/or edema, and finally acral redness and flushing[23].

2.7. Creation of diaphragmatic hernia

On GD23, does underwent surgery under general anesthesia for induction of a left-sided diaphragmatic defect as previously described (further referred to as congenital diaphragmatic hernia, CDH)[9,21,24]. The anesthesia protocol and surgical procedure is detailed in supporting information (SI2). Briefly, the surgical procedure consisted of a lower-midline laparotomy followed by sequential hysterotomy and fetal thoracotomy to eventually excise a portion of the left diaphragm. This was done in maximum five fetuses per doe, based on the litter size and whether the total operating time could be kept under 1h15. After the surgery, does were returned to their cages with free access to water and food, and monitored daily for pain.
At term (GD31), does were sedated with intramuscular (IM) ketamine (0.5 mg/g, Nimatek®, Eurovet Animal Health BV, Bladel, The Netherlands) and xylazine (0.1 mg/g, XYL-M®, VMD, Arendonk, Belgium), followed by gas anesthesia using isoflurane (1.5%, ISO-VET®, Piramal Critical Care, Voorschoten, The Netherlands). After local infiltration of lidocaine (4 mg/kg, Xylocaine®, Aspen, Dublin, Ireland) a laparotomy and hysterotomy were performed to deliver the pups. All pups were weighed and either sedated with an intraperitoneal injection of ketamine (35 mg/kg, Nimatek®) to undergo mechanical ventilation or transcardial perfusion, or were immediately decapitated with sharp scissors to harvest the organs in a fetal state, prior to the first breaths. After delivery of the last pup, does were euthanized using IV 140 mg/kg pentobarbital (Euthasol®, Dechra, Bladel, The Netherlands).

For the spatio-temporal receptor expression study, unventilated lungs were divided. Left lungs were immersed in 4% paraformaldehyde (PFA) in 0.1 mol/L phosphate buffer (Klinipath®, Sowinski, Poland) with pH 7.4, whereas right lungs were snap frozen in liquid nitrogen and stored in baked aluminum foil for molecular analysis.

For the dose-finding and tolerance study, four pups per litter underwent transcardial perfusion for neuropathological examination (technique detailed in supporting information (SI3)). In the remaining pups, blood was collected via decapitation and hearts, left kidneys and placentas harvested and submerged in 4% paraformaldehyde (PFA). The lungs were dissected ‘en bloc’ and an angiocatheter (18–20 G) secured in the trachea. After tying off the right main stem bronchus, PFA was instilled in the left lung at a distending pressure of 20 cmH2O during at least three hours. Right lungs were snap frozen with liquid nitrogen and stored in baked aluminum foil for molecular analysis. After euthanasia,
ribs were manually counted in all pups of the litter. For the efficacy study, litters were either dedicated to pulmonary function testing or fetal organ and lung harvest, as described for the dose-finding and tolerance study section. In operated pups, the presence of CDH was visually confirmed upon dissection.

2.10. Histology

Organs harvested for histology remained immersed in PFA during 48 h whereupon their volumes were determined using the fluid displacement method [25]. Organs were then transferred to ethanol (70%), dehydrated (70% ethanol, 90% ethanol, 99% ethanol, toluol), embedded in paraffin, sectioned coronally, stained and analyzed in an organ-specific manner as detailed below. Histological slides were digitized using a Zeiss AxioScan Z1 (AxioScan Slide Scanner, Carl Zeiss MicroImaging GmbH, Munich, Germany) and analyzed blinded to the study group.

Lungs were stained with hematoxylin and eosin (H&E), or with antibodies α-smooth muscle actin (α-SMA, mouse anti-human, M0851; DakoCytomation, Glostrup, Denmark), prostaglandin E2 receptor (ab167171, Abcam, rabbit monoclonal EPR8030B) or prostacyclin receptor (GTX71509, GeneTex, Irvine, CA, USA) (validation detailed in Fig. S3.). Horseradish peroxidase (ab2338503, goat anti-mouse, and ab2313567, goat anti-rabbit, polyclonal, Jacksonimmuno) was used as secondary antibody. Airway morphometry was assessed in 10–35 (depending on the lung size) randomly selected tiles per lung (500×500 µm), using a validated semi-automated ImageJ analysis tool quantifying alveolar septal volume density (Vvsep), alveolar mean linear intercept (Lm), mean transsectional wall length (Lmw) and alveolar surface area density (Svair) [26]. Alveolar mean linear intercept (Lma) and alveolar surface area (S) were calculated using the methodology put forth by the American thoracic society [27]. Vascular morphometry was performed manually on slides stained with α-SMA, using the ZEN Microscopy Software (Zen Blue, Carl Zeiss, Oberkochen, Germany). Pulmonary arterioles were distinguished from pulmonary veins based on position and

Fig. 2. Maternal and foetal treprostinil concentrations. Treprostinil concentrations were measured in does with term pups exposed to eight days of treprostinil at different doses 50 (C.T.50), 100 (C.T.100) or 150 (C.T.150) ng/kg/min. N = 3 does per dose, with three foetuses per litter. Bars represent median concentrations. The lower limit of quantification was 0.025 ng/mL.

Fig. 3. Maternal tolerance. a Tolerance study design and colour legend. b Delivery date per group. c Maternal weight over time (kg). d Maternal weight change over time relative to baseline weight (weight t - weight t0GD23), corrected for litter size. e Daily maternal heart rate in beats per minute (bpm). f Change in maternal heart rate relative to baseline (heart rate t - heart rate t0GD23). g Daily food intake (grams). h Behavioural assessment scores (/22) over time. i Daily rabbit grimace score (/10). j Pump-site oedema over time. Transparent bars represent the number of does at given GD. Solid bars represent does with oedema at the pump-site per group. For graphs 3c-f. full lines represent medians, and dotted lines the interquartile range. For graphs 3 g-j. full lines represent medians, and dotted lines the range. Number of does per group were CTRL (n = 4), C.T.50 (n = 3), C.T.100 (n = 4) & C.T.150 (n = 4). * The C.T.100 rabbit with poor behavioural and grimace scores, also ate less and ultimately delivered prematurely on GD29.
Fig. 4. Foetal safety. Only pups from term litters were analysed. a Colour legend. b Foetal survival per litter (%). c Foetal body weight (FBW) in grams, nested per litter. d Heart volume/FBW ratio, nested per litter. e Brain volume/FBW ratio, nested per litter. f Percentage of pups per litter with 12 or 13 pairs of ribs counted. g Placental volume/FBW ratio, nested per litter. h Proportional surface area of per placental zone (%). i Image of a cytotheratin/lecint stained placental section with zone-surfaces areas delineated: the decidua in yellow, junctional zone in blue and the labyrinth in red. The scale bar represents 1 mm. j Representative histological image of the placental labyrinth zone stained with cytokeratin and lectin. MBS maternal blood space, FC foetal capillary and TB trophoblast cells. White scale bars represent 40 μm. k Proportional placental labyrinth cell count (%). l Kidney volume/FBW ratio, nested per litter. m Proportion of mature nephrons (%). n Proportion of nephrons per glomerular developmental stage (%). o Proportional renal zone surface area distribution (%). p Representative image of renal zone surface area distribution assessment on H&E-stained section. The nephrogenic zone is delineated in yellow, the cortex in red and the medulla in blue. The scale bar represents 800 μm. q Proportion of renal cortical tissue staining positively for lectin (%). r Representative images of pressure-fixated lungs stained with haematoxylin-eosin (H&E) and a smooth muscle actin (α-SMA). Bars represent 100 μm. s-v Airway morphometry; Vsnap = volume density of alveolar septa, Lm = mean linear intercept of airspaces, Lm = mean transsectional wall length and S vap = surface area density of air spaces. w Proportional medial wall thickness of pulmonary arteries. x Lung volume/FBW ratio, nested per litter. Full lines represent means and error lines represent standard deviations. Number of foetal pups is indicated at the bottom of bar graphs. One-way ANOVA with Dunnnett’s multiple comparison test was performed with the CTRL group as reference (b,h,k,m-0,q,s,v,w and nested per litter: c,d,e,g,l,x). Kruskal-Wallis multiple comparison test with CTRL as reference was performed for Lm and %MWT (t,w). Student’s t-test was used to compare rib counts (f). *p < 0.05, **p < 0.01, ***p < 0.001.

structure. Only those pulmonary arterioles were considered that were approximately round (i.e. two perpendicularly measured internal diameters (ID) were not different >50%) and the mean ID was ≤100 μm. The mean external diameter (ED) as well as measured internal diameters were then measured, and the proportional median wall thickness (%MWT), a surrogate maker of pulmonary hypertension, calculated as follows: %MWT = [(ED-ID)/EDx100] [28]. Arterioles were further categorized in three groups according to the external diameter (ED): i.e. intra-acinar (ED<30 μm), ED between 30 and 60 μm, and pre-acinar (ED 60–100 μm). Quantification of Sirius Red, PTGER-2 and PTGIR stain was performed using custom ImageJ macros of which the code is provided in the supporting information (S14).

For cerebral histology, four serial coronal sections (thickness 4 μm) were taken at 50 μm intervals at the level of medial septal nucleus (for examination of the frontal cortex (FC) in the internal pyramidal layer and the caudate nucleus (CN)) and another four at the level of the hippocampal formation (for investigation of the hippocampal CA3 region and the dentated gyrus (DG)) [29]. Sections were stained with Cresyl-Violet (Cresyl-Violet acetate, Sigma-Aldrich®, Darmstadt Germany) and for brightfield immunohistochemistry primary antibodies used were mouse monoclonal anti-human Ki67 (M724001-2, Agilent, Diegem, Belgium) for proliferation, Glial Fibrillary Acidic Protein (GFAP, G6171, Citeab, Bath, UK) for astrocytosis, Neuroglial antigen 2 (NG2, AB53841-1, MerckMillipore, Burlington, MA, USA) for oligodendrocyte progenitor cells and biotinylated isocitrate B4 (B-1205, Vector Laboratories, Burlingame, CA, USA) for microvascul summarization [30]. The secondary antibody was goat anti-mouse peroxidase (115044, Vector Laboratories, Burlingame, CA, USA). The sections were counterstained with Hoechst 33342 (Sigma-Aldrich) [29]. Histogramical quantification was performed in the FC, CN and the hippocampus, using the open-source QuPath (version 0.2.3, Centre for Cancer Research & Cell Biology, Queen’s University Belfast, Belfast, Northern Ireland, Open source) [31] and ImageJ (Version 1.51 g, Fiji, USA) [32]. Per slide, three random squares (100 ×100 μm) were selected on low magnification: (1) in the internal pyramidal layer of the frontal cortex, (2) the caudate nucleus and (3) in the hippocampus CA3 region. In the hippocampus, neurons were counted in the lateral 500 μm of the dentate gyrus. Neuron density was counted manually on Cresyl-Violet-stained slides. Neuron densities were expressed as number of neurons per mm2 or as number of neurons per mm in the dentate gyrus. Neuron densities were counted on three consecutive slides and their average was reported [30]. TUNEL, Ki67 and NG-2 positive cells were counted using the positive cell detection function in QuPath under either bright-field or fluorescent positive cell detection settings [29, 30]. The detection classifier function was used to differentiate between cell types [31, 33]. Positive cell counts were expressed as a percentage of positive cells per total cells detected.

Quantification of lectin and GFAP stain, were performed using custom ImageJ macros of which the code is provided in the supporting information (S15).

A coronal section through the middle of both placental lobes was stained with cytokeratin (nb600–579, Novus Biologicals; 1:75, overnight, 4 °C) and lectin (Isocitric B4, B-1205, Vector Laboratories; 1:250, 90 min, 37 °C), to differentiate cytotrophoblasts and fetal capillaries in the labyrinth zone respectively [34]. The proportion of fetal capillaries, maternal blood spaces and cytotrophoblasts within the labyrinth was determined on ten random fields at 40x magnification using a 5 × 2 point counting grid (100 points analyzed per placenta) [34]. Proportional surface areas of the labyrinth, decidua and junctional zone were measured using the QuPath wand tool.

A coronal section through the middle of the renal pelvis was stained with H&E and biotinylated isocitric lectin. Proportional surface area of the medulla, cortex and nephrogenic zone were measured using the QuPath wand tool over the entire slide. Glomerular maturity was scored as previously described, in the upper, medial quadrant by two observers (FRDB & AD) [35].

2.11. Lung mechanics testing

Lung mechanics tests were performed using the FlexiVent 5.2 (SCIREQ, Montreal, Canada) on anesthetized neonatal pups from dedicated litters. A tracheostomy was performed to insert a 18 G metal cannula and start lung-recruitment breaths (RR: 120 breaths/min, tidal volume: 8 mL/kg, PEEP: 3cmH2O). Once the inspiratory capacity (IC) reached a plateau, triplicate measurements were obtained of a series of pulmonary function tests consisting of (1) an IC measurement, (2) a single-frequency oscillation (Snapshot 150: a single-frequency measurement at 2.5 Hz) to assess dynamic compliance (Crs), (3) a broadband oscillation maneuver (Primewave-B: measuring respiratory impedance from 0.5 Hz to 19.5 Hz) to assess tissue stiffness, and (4) pressure-volume maneuvers (PVr-P: continuous increase of airway pressure to 13 cmH2O, PVs-P: staged increase of airway pressure to 30 cmH2O) [36, 37]. IC and Cst were corrected for weight. When system-detected errors could not be corrected or the ultimate IC was not > 50% higher than the first IC, pups were excluded from analysis.

2.12. Western blot

Tissue samples were mechanically homogenized in RIPA lysis buffer (10 mM sodium phosphate (pH 7.5), 150 mM NaCl, 1.5 mM MgCl2, 0.5 mM EDTA, 1% Triton X-100), with protease- and phosphatase inhibitors (11836159001, eComplete™, Roche, Basel, Switzerland). Protein concentration was determined using a Pierce BCA Protein Assay Kit (23225, Thermo Fisher Scientific). Equal quantity (μg) of samples was prepared with SDS buffer containing β-mercaptoethanol, heated at 95 °C for 5 min and 15 μL loaded on NuPAGE 4–12% Bis-Tris gels (NP0321BOX, Thermo Fisher Scientific). SDS-PAGE was performed with a constant voltage of
Fig. 5. Cerebral morphometry. a Representative cerebral section through the frontal cortex (FC) and the caudate nucleus (CN). Measurements were performed in the internal pyramidal layer of the FC and the CN (zones marked in red). Scale bar represents 1 mm. b Representative cerebral section through the hippocampus. Measurements were performed in the dentated gyrus (DG) and CA3 region of the hippocampus (zones marked in red). Scale bar represents 1 mm. c Quantified (immuno-) histochemical analysis per region. Cresyl-Violet was used for neuron density count in the FC, CN and DG. TUNEL-positive cells indicated apoptosis in the FC, CN and CA3. Proliferation was assessed by means of positive Ki67 cell counts in the FC, CN and CA3. Oligodendrocyte-precursor cells were counted as NG2 positive cells in the FC, NC and CA3. Lectin surface area was quantified and expressed in proportion to the total cell surface area in the FC, CN and CA3. Astrocytosis was assessed quantifying the surface area of GFAP expressed in proportion to the total cell surface area in the FC and CA3. Full lines represent means and error lines represent standard deviations. Number of fetal pups was indicated at the bottom of bar graphs. Data were compared using Dunnett’s multiple comparison test with the control group as reference.

160 V during one hour. Next, proteins were blotted on polyvinylidene difluoride (PVDF) transfer membranes (88518, Thermo Fisher Scientific) using the Mini Blot module set (B1000, Thermo Fisher Scientific) for 2 hours at 30 V. Membranes were blocked for one hour at room temperature with PBS-Tween (0.1%) containing 5% milk powder (MP) followed by incubation with the PTGIR-2 primary antibody (ab67171, Abcam, Cambridge, UK) diluted in PBS-T and 2% MP overnight at 4 °C. Next day, the membranes were washed three times with PBS-T and then incubated with the secondary horseradish peroxidase (HRP)-coupled antibody (P044801–2, goat anti-rabbit, Agilent) for 45 min with PBS-T + 2%MP. After washing three times with PBS-T, immunoreactive bands were visualized through enhanced chemoluminescence (Pierce ECL Plus Western Blotting Substrate, SuperSignal West Dura, 34075, Thermo Fisher Scientific), followed by serial exposure and detection with the G: Box GelDoc system from Syngene (Cambridge, UK). Intensity quantification was performed on unsaturated bands with ImageJ [38].

2.13. Quantitative polymerase chain reaction

mRNA was extracted using the Tri-Pure® Isolation reagent (Roche Diagnostics, Germany) and its concentration measured using the Nanodrop 1000® spectrophotometer (Thermo Fisher Scientific). Agarose gel electrophoresis was used to verify RNA integrity (integrity of 18 S and 28 S bands). TaqMan™ Reverse Transcription Reagents (Thermo Fisher Scientific) was used for cDNA synthesis. For detection the Platinum SYBR Green qPCR Supermix-UDG with ROX (Thermo Fisher Scientific) was used, followed by serial exposure and detection with the G: Box GelDoc system from Syngene (Cambridge, UK). TaqMan™ assay (P044801–2, goat anti-rabbit, Agilent) for 45 min with PBS-T + 2%MP. After washing three times with PBS-T, immunoreactive bands were visualized through enhanced chemoluminescence (Pierce ECL Plus Western Blotting Substrate, SuperSignal West Dura, 34075, Thermo Fisher Scientific), followed by serial exposure and detection with the G: Box GelDoc system from Syngene (Cambridge, UK). Intensity quantification was performed on unsaturated bands with ImageJ[38].

2.14. Enzyme-linked immune-sorbent assay (ELISA)

Tissue samples were mechanically homogenized in RIPA lysis buffer containing Tris-HCL and EDTA. Cyclic adenosine monophosphate (cAMP) was quantified using a commercial ELISA kit (MBS2600879, Mybiosource.com, San Diego, CA, USA) according to the manufacturer’s protocol.

2.15. RNA sequencing

Total RNA was extracted using the RNeasy mini kit (Qiagen, Hilden, Germany) according to the manufacturer’s instructions. Initial quality control was performed using the Bioanalyzer 6000 Nano. Sequencing was performed by Azenta (Azenta Life Sciences, Griesheim, Germany). The methodology is detailed in the supporting information [S16]. The Illumina NovaSeq platform was used on poly-A selected mRNA with 2 x 150 pair-end reads. Trimmed reads (Trimmomatic v.0.36) were aligned to the rabbit genome reference (OryCan2.0) using STAR aligner v.2.5.2h. Differential gene expression was performed using R-studio (2022.12.0) with the DESeq2 library [40]. We included genes with a count per million greater than 1 in at least two samples. Significant differential gene expression was determined using an adjusted p-value less than 0.05 and a log2 fold change (log2FC) greater than 1 or less than –1 as cut-offs.

2.16. Sample size

For the receptor and tolerance study no power calculation was performed. For the dose-finding study, three doses per group were used as is customary for maternofoetal pharmacokinetic studies [21]. For the efficacy study, based on previous studies [21,41] we determined using G*nPower [42], that 6–7 foetuses/group would provide a power of ≥ 90% with a two-sided type I error of 5%, to detect a 10% reduction in %MWT (primary study outcome).

2.17. Statistics

The Shapiro-Wilk test was used to assess the distribution of variables. Normally distributed values were expressed as means ± standard deviations and analysed with t-test or one-way analysis of variance (ANOVA) with Dunnett’s multiple comparison test to assess differences between groups. Non-normally distributed values were presented as medians and interquartile ranges and analysed using the Kruskal-Wallis test with multiple comparisons testing. Organ and foetal body weights were analysed using nested analysis to correct for litter-specific influences. A complete overview of outcome measures, their distribution, the statistical tests used and the F (ANOVA) and t-values (t-tests) with degrees of freedom are provided in Table S3. Significance was determined as p < 0.05. Data was analyzed using Prism version (GraphPad, San Diego, CA, USA).

3. Results

3.1. Pulmonary PTGER-2 and PTGIR expression progressively increase throughout gestation

We first mapped the spatio-temporal pulmonary expression of the two receptors that mediate treprostinil’s antiremodeling effect, i.e. prostaglandin E2 (PTGER-2) and prostacyclin (PTGIR) [17,43]. Lungs of unoperated pups and pups with CDH were harvested at the following gestational ages, each representative of a specific lung developmental stage: gestational day (GD) 20 pseudoglandular, GD25 canalicular, and GD31 (=term) alveolar (Fig. 1a) [44]. Receptor expression was assessed by immunohistochemistry and quantified with quantitative polymerase chain reaction (qPCR) and western blotting (WB). PTGER-2 and PTGIR were primarily expressed in the respiratory epithelium and pulmonary arterioles (Fig. 1b & Fig. S1). Quantification of PTGER-2 and of PTGIR expression per lung tissue area demonstrated respectively stable and increasing ratios over lung developmental stages in unoperated pups (Fig. 1c,d). PTGER-2 protein expression increased with gestation in lungs of unoperated pups, however, was markedly lower in term pups with CDH (Fig. 1e). mRNA expression for both receptors gradually increased over gestation both for lungs of control and CDH pups (Fig. 1f, g).

3.2. Treprostinil crosses the placenta

Next, we sought to investigate transplacental transfer of continuous
subcutaneous maternal administration of treprostinil. Programmable drug infusion pumps were implanted in the maternal neck scruff on GD23. At term (GD31), blood was collected from does and foetuses for treprostinil plasma concentration determination using ultra high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS). Examined doses were determined based on toxicity experiments in pregnant rabbits as part of treprostinil’s New Drug Application (NDA) at the Food and Drug Administration. Since these studies reported maternal side effects (reduction in food intake and body weight) at a dose of 150 ng/kg/min, we used 50 (Control-Treprostinil 50, C.T.50), 100 (C.T.100) and 150 ng/kg/min (C.T.150)[23]. Maternal and fetal concentrations were dose-dependent (Fig. 2), with only the highest dose (150 ng/kg/min) consistently attaining fetal concentrations above the lower limit of quantification (0.025 ng/mL) with an average transplacental transfer ratio of 1.66% (± 0.61%).

3.3. Treprostinil is tolerated by does and increases glomerular maturation and pulmonary arteriolar hypermuscularization in foetal pups

In parallel to the pharmacokinetics, we assessed maternal tolerance and foetal safety in unoperated animals exposed to treprostinil at 50, 100 and 150 ng/kg/min as compared to placebo (NaCl 0.9%, CTRL group). Three term-delivered litters were obtained per group. Maternal heart rate, weight, food intake, pain, behaviour, and pump site were assessed daily, starting one day prior to the pump implantation (GD22) until delivery at term (Fig. 3a). Three does spontaneously delivered preterm: one in the CTRL (GD30), one in the C.T.100 (GD29) and one in the C.T.150 group (GD30) (Fig. 3b). Maternal weight gain and heart rate did not differ in treated groups compared to unexposed controls (Fig. 3c-f). After pump implantation, does receiving treprostinil had a temporary (one day) reduction in food intake, regardless of the dose (Fig. 3g). In two does (C.T.50 & C.T.100), food intake remained lower for the remainder of the pregnancy. Maternal behavioural and pain scores were not different in treprostinil-exposed groups from those in the unexposed controls. Oedema at the pump-site was noted day one after implantation in almost all does exposed to treprostinil, regardless of the dose, however not in the CTRL group. In does receiving 50 ng/kg/min treprostinil, oedema regressed over the course of four days. In does with 100 and 150 ng/kg/min oedema persisted longer (Fig. 3j).

Only foetuses from term litters were analysed. Foetal survival and body weight were not different among groups (Fig. 4b,c). The volumes of hearts, brains, placenta, left kidneys and lungs relative to body weight from treprostinil-exposed foetuses did not differ from controls (Fig. 4d,e,g,l,x). The anatomical variation of an additional 13th rib was equally prevalent in C.T.150 and CTRL groups (Fig. 4f). No morphological differences were observed between placenta from different groups (Fig. 4h-k). Alveolar septal thickness, sepal volume and surface area density were not altered by treprostinil administration (Fig. 4l-o). Interestingly, pulmonary arteriolar proportional smooth muscle wall thickness (%MWT) was increased in treprostinil-exposed foetuses independent of the dose (Fig. 4r,w). There was no change in the ratio of renal cortex, medulla, and nephrogenic zones, or renal cortical vascularity in foetuses exposed to treprostinil, however the proportion of mature nephrons was higher (Fig. 4m-q). Cerebral immunohistochemical analysis revealed no measurable effects on neuron density, apoptotic cell count, cellular proliferation, oligodendrocyte progenitor cells density, microvascularization and astrocytosis in foetuses exposed to treprostinil (Fig. 5c).

3.4. Treprostinil reduces pulmonary arteriolar hypermuscularization in term CDH pups

Having demonstrated consistent foetal-maternal transfer and acceptable maternal and foetal tolerance of 150 ng/kg/min treprostinil, we investigated its effects in rabbit foetuses with CDH. On GD23, CDH was surgically created in selected pups, and does were exposed to either saline solution (CDH group) or treprostinil (CDH + TRE group) using a subcutaneous pump placed in the maternal neck scruff. Infusion was programmed to start 24 h after implantation until caesarean section at term (Fig. 6a). Unoperated littermates constituted the controls, either exposed to treprostinil (CTRL + TRE group) or not (CTRL group). As expected, pups with CDH displayed a higher pulmonary arteriolar % MWT than CTRL (41.1 ± 2.3% vs 29.3 ± 4.4%, p < 0.0001). The %MWT in the CDH + TRE group was significantly lower than in placebo-exposed CDH (33.4 ± 3.4% vs 41.1 ± 2.3%, p = 0.0003) in all vessels < 100 µm, and most pronounced in the smaller-sized vessels (<30 µm) (Fig. 6d). % MWT was increased in CTRL + TRE pups relative to CTRL (36.0 ± 1.7% vs 29.3 ± 4.4%, p = 0.0016) (Fig. 6e-e).

3.5. Lung hypoplasia, airway and extracellular matrix morphology in pups with CDH remain unchanged following treprostinil exposure

Ipsilateral, left lung volumes relative to foetal body weights were lower in pups with CDH, regardless of treprostinil exposure (Fig. 6b). Alveolar sepal density (Vvsep) was higher in CDH than CTRL pups and not different after prenatal treprostinil exposure. Similarly, alveolar mean linear intercept (Lma), volume (Vair/LV) and surface area relative to the left lung volume (S/LV) were impaired in CDH, and not altered with treprostinil exposure (Fig. 6f-j). Airway morphology was not different between CTRL and CTRL + TRE groups. Quantification of Sirus Red stain suggested comparable collagen I and III deposition when expressed proportional to total tissue area (Fig. 6k-m).

3.6. Treprostinil does not improve pulmonary mechanics in CDH

A dedicated subset of pups from all four groups were ventilated immediately after birth for invasive lung mechanics assessment. Lung mechanics parameters both during pressure-volume and forced oscillation manoeuvres were significantly different in pups with CDH compared to CTRL, and similar observations were made in treprostinil-exposed pups. In pups without CDH, treprostinil administration did not affect pulmonary mechanics (Fig. 7).

3.7. Treprostinil downregulates inflammation, coagulation and myogenesis in CDH without affecting receptor expression

To characterize the mechanism of action of treprostinil on pulmonary vascular development, we performed RNA sequencing on unventilated left lungs lobes of CDH, CDH + TRE and CTRL pups (n = 2–3/group). We observed a positive enrichment of interferon alpha and gamma in lungs of pups with CDH compared to CTRL (Fig. S2). Principal component analysis revealed clustering of CDH + TRE separate from
Pressure-Volume maneuvers

Forced Oscillation maneuvers

(caption on next page)
CDH, and together with CTRL in principle component 1 (Fig. 8a). Differential gene expression analysis using a cut-off value of \( \log_2 \) fold change >1% and 5% FDR reveals 97 upregulated and 82 downregulated genes when comparing CTRL with CDH and 33 upregulated and 71 downregulated genes when comparing CDH versus CDH-TRE (Dataset S1&S2). Of the 97 upregulated genes in pups with CDH, 23 were downregulated when exposed to treprostinil (Fig. 8b, Dataset S3). We next performed gene set enrichment analysis of CDH versus CDH-TRE lungs using the hallmark gene set of the Molecular Signatures Database. We found significant enrichment (5% FDR) of 15 gene sets (Fig. 8c, Dataset S4&S5). Among those gene sets, we identified enrichment for genes downregulated in CDH-TRE pups related to coagulation, inflammatory response, complement activation, and myogenesis (Fig. 8c,d). These pathways correspond to the known mechanisms of action of treprostinil. Upregulation of mitochondrial transcripts and genes involved in the oxidative phosphorylation pathway was also observed in treprostinil treated pups with CDH (Fig. 8c,e).

Compared to CTRL, pulmonary PTGER-2 protein expression was not different in CDH pups, however, was increased in CTRL+TRE (p = 0.0029) (Fig. 9a). PTGER-2 mRNA expression was increased in CDH, however not altered by treprostinil (Fig. 9b). PTGIR and its synthase (PTGIS) were not consistently affected by CDH and/or treprostinil exposure (Fig. 9c,d). Cyclic adenosine monophosphate (cAMP), a key downstream regulator in the prostacynin pathway was slightly higher in treprostinil-exposed pups, however this was not significant (Fig. 9e).

4. Discussion

We first demonstrated the expression of treprostinil’s target receptors at relevant timepoints during gestation in control and CDH pups. Next, we quantified transplacental passage of maternal treprostinil into the foetal circulation without limiting adverse effects in does and foetuses at doses up to 150 ng/kg/min. Subsequently, in foetal rabbits with surgically created CDH, prenatal exposure to treprostinil (150 ng/kg/min) prevented the hallmark hypermuralization of pulmonary arte- rioles (<100 µm) and was associated with downregulated molecular pathways involved in inflammation, coagulation and myogenesis. No effect on airway morphometry and lung mechanics was observed. In foetuses with normal lung development, prenatal treprostinil exposure increased pulmonary arterial wall thickness.

We corroborated our previous findings in the nitrofen rat model in a larger model with lung development more similar to humans[2]. Unlike rodents, rabbits and humans undergo alveolarization in utero[41]. Surgical induction of CDH in rabbits during the pseudoglandular lung developmental phase reproduces the clinical phenotype in terms of pulmonary airway and vascular morphometry, as well as pulmonary function testing[24,45]. The rabbit model is also better suited for study in the nitrofen rat model of CDH, we therefore aimed to attain foetal concentrations above 0.5 ng/mL, which is the lowest reported effective (vasodilative) neonatal concentration[52]. However, we demonstrated that foetal concentrations of treprostinil below 0.5 ng/mL sufficed to exert treprostinil’s anti-remodelling effect[2]. Similarly, in this rabbit study we observed that treprostinil concentrations lower than 0.025 ng/mL (C.T.50 and C.T.100), were already associated with biological activity, i.e. increased %MWT and increased glomerular maturation.

We performed a comprehensive analysis of maternal tolerance and foetal safety at different doses of treprostinil. Doses exposed to treprostinil demonstrated temporary reduction of food consumption mainly on the day after drug initiation, an observation consistent with rabbit studies performed for the NDA of treprostinil[23]. We also observed pump site oedema of which the duration was congruent with the dose. In clinical studies investigating SC treprostinil administration, up to 85–92% of participants report incidental pump site reaction (swelling, redness, rash, and pain)[3,4]. Both the lesser food intake and the pump site oedema were temporary for all doses and were not associated with worse pain or neurobehavioral scores. Contrary to what studies in pregnant rabbits reported in treprostinil’s NDA, we did not observe an increased incidence of a thirteenth rib in the offspring exposed to the same maternal dose of treprostinil (150 ng/kg/min). We speculate this is most likely due to the later administration of treprostinil in our study, well past the embryological developmental phase[23].

In foetuses exposed to treprostinil, we observed increased renal glomerular maturation. In human kidneys, PTGIR and PTGER-2 are abundantly expressed in the nephrogenic cortex[55,56]. The severely distorted renal glomerular, vascular, and interstitial development in PTGIS-knockout mice further confirms prostacyclin’s vital role in normal renal development[55,57]. Antenatal corticosteroids have been demonstrated to similarly accelerate renal morphologic maturation in preterm baboons[58], which clinically resulted in improved renal function in neonatal life[59].

Prenatal treprostinil also affected pulmonary vascular development in control foetuses, increasing the arteriolar %MWT and thus creating a hypertensive phenotype. We also observed this phenomenon in rats with normal lung development prenatally exposed to treprostinil[2]. Similarly, prenatal exposure of control rats and rabbits to sildenafil, a phosphodiesterase 5 inhibitor with anti-remodelling effects, increased the %MWT and reduced vascular branching[6,61]. Although the mechanism behind these observations remains unclear, one could imagine that in response to the vasodilatory agent, the foetus mounts a
Fig. 8. Transcriptome analysis. a Principle component analysis (PCA). b Venn diagram displaying the number of deregulated genes. The genes are detailed in the supplemental table 3. c Hallmark gene sets that are significantly enriched for genes that are up- or downregulated based on gene set enrichment analysis (GSEA; 5% FDR). d Gene set enrichment plots of coagulation, complement, inflammatory response and myogenesis. e Heatmap containing the 50 most up- and downregulated genes (selected by Log2FC) from CDH and CDH + TRE from three biological replicates per group. Colour represents row-scaled, normalized read counts. NES = normalized enrichment score.
compensatory vasoconstrictive reaction to restore minimal pulmonary circulation. Prolonged vasoconstriction may prevent the physiologic arteriolar thinning of the media towards the end of gestation, resulting in the relative hypermuscularization we and others have described[2,28, 60,61]. Moreover, we have argued before that these structural vascular changes may provide at least a partial answer to the findings in the Dutch arm of STRIDER (Sildenafil Therapy in Dismal Prognosis Early-Onset Foetal Growth Restriction) trial [62,63]. This study investigating foetal sildenafil for severe foetal growth restriction was stopped early, after higher-than-expected neonatal mortality and persistent pulmonary hypertension of the new-born was noted upon interim analysis [64,65]. Wary of these findings, we infer that clinical trials with prenatal administration of treprostinil in conditions with normal lung development should be strongly dissuaded.

The rabbit model has been extensively used for the study of perinatal brain development resulting from perinatal insults, demonstrating histologic brain changes associated with neurobehavorial impairment after for example fetal surgery, antenatal corticosteroids, and fetal growth restriction [29,66,67]. We performed extensive histological brain analysis and did not find differences in treprostinil-exposed pups.

Treprostinil administration was started on GD24, during the early canalicular lung development phase. This timepoint is relevant since it correlates with a human equivalent of 18 weeks’ gestation which is when CDH is usually diagnosed on prenatal ultrasound [44,68,69].

The primary outcome of this study was the %MWT of small pulmonary arterioles (ID<100 μm, up to the pre-acinar vessels) which constitute the resistance vasculature of the lung [70]. The %MWT quantifies vascular muscularization and is a well-described hallmark of postnatal persistent PH [24,28,71-73]. Corroborating our findings in the nitrofen rat model, we found that the %MWT was lower in CDH+TRE pups than unexposed CDH pups, especially in the lower calibre pulmonary arterioles [2]. During normal lung development, progressive thinning of the media and adventitia is observed over the course of gestation in preparation for massive pulmonary vasodilatation at birth [28]. Reversal of the hypermuscularized pulmonary arteriole phenotype observed in treprostinil-treated CDH pups would be predicted to attenuate the postnatal PH characteristic of this disorder.

Despite treprostinil’s distinct effect on pulmonary arteriolar development, we did not observe an effect on alveolar morphometry, lung mechanics or overall ipsilateral lung hypoplasia. Although this confirms our findings in the rodent model of CDH, this contrasts with the findings of prenatal sildenafil in CDH [21,60]. While treprostinil and sildenafil act on different pathways (prostacyclin & nitric oxide pathways respectively), the timing of administration may also have played a role. Studies assessing prenatal experimental prostacyclin-analogues (NS-304 and ONO-1301SR) in the nitrofen-rat model have demonstrated improved airway development only when administered early, i.e. during the embryonic lung developmental phase (human equivalent of 4–7 weeks gestation) [44,74,75]. However, such early administration cannot be clinically translated since the clinical diagnosis of CDH is typically made on ultrasound, typically much later around gestational week 20 [69].

FETO is a clinically validated surgical procedure shown to stimulate prenatal pulmonary parenchymal development and to increase lung size in foetuses with CDH [5,6,24,76]. Treprostinil and FETO have complementary effects on prenatal lung development, and we speculate that when combined they could act synergistically, as was observed with sildenafil [9].

We also investigated the effect of treprostinil on pulmonary extracellular matrix (ECM) remodelling. cAMP, a down-stream regulator of treprostinil involved in ECM metabolism and proliferation control, trended slightly higher in treprostinil-exposed lungs. However, we did not observe decreased collagen type I deposition in pups exposed to treprostinil, which contrasts findings from in-vitro studies [16]. Concordantly, pulmonary functional characteristics (compliance, elastance, resistance and reactance) were not improved in pups with CDH after prenatal treprostinil exposure.

The positive enrichment of interferon alpha and gamma (both pro-inflammatory cytokines) we observed in lungs of pups with CDH is in line with a study demonstrating significantly increased levels of interferon alpha in cord blood of CDH neonates [77]. Others have suggested that inflammatory pathways play a crucial role in the pathophysiology of CDH and that anti-inflammatory agents may provide therapeutic benefit in CDH [78,79]. Treprostinil has an established anti-inflammatory effect that is reflected in the downregulation of gene sets involved in complement and inflammatory pathways (Fig. 9c). The downregulation observed in the myogenesis and coagulation pathway gene sets is consistent with treprostinil’s other known mechanistic effects i.e. anti-remodelling and anti-aggregation respectively. Finally, the pattern of the observed pulmonary PTGER-2 protein expression perfectly reproduces the findings of our rat study [2].

This study has several limitations. First, the surgical rabbit CDH model only reproduces the thoracic compression caused by herniation of abdominal organs, not a potential primary insult prior to diaphragm development as hypothesized in the dual-hit hypothesis and reproduced in the nitrofen rat model [80]. Second, the timing of CDH creation and treatment nearly coincided, which is not ideal from a pathophysiological point of view. We did so to allow a sufficient long exposure given the short duration of rabbit gestation and to screen for a maximal effect of treprostinil, however accepting the risk to overestimate it. Third, we could not assess neonatal pulmonary pressures and blood gases, because in our experience rabbit pups cannot survive long enough due to the severe lung hypoplasia. Fourth, in an effort to reduce the number of animals needed, we harvested the contralateral, right lung for molecular analysis, and the ipsilateral, left lung for histology. Although both lungs are developmentally abnormal in CDH [81], the effect of local
compression is more pronounced in the ipsilateral lung\cite{82}. The local effect on molecular and protein expression could therefore also be different from what we observed in the contralateral lung. Finally, we opted for continuous SC treprostinil administration for practical reasons, as it has the same bioavailability as IV administration\cite{83}. Clinically, SC administration would be a burden to pregnant mothers. Alternatively, an extended-release oral formulation of treprostinil (Orenitram, United Therapeutics, Silversprings, MD) was approved and is now available in the US\cite{84}.

Finally, although treprostinil does not improve airway in addition to pulmonary vascular development as seen with sildenafil, it has the critical advantage that it has not yet been investigated for any other prenatal indication. This allows the investigation to be targeted and to avoid a moratorium for clinical translation as is the case with sildenafil after the STRIDER-trial\cite{2,85,86}.

5. Conclusion

This study demonstrates that, in the rabbit, treprostinil’s target receptors are present at relevant timepoints during gestation, and that prenatal treprostinil is well-tolerated by the does and foetuses. In rabbit pups with CDH, treprostinil effectively prevents hypermuscularization of pulmonary arterioles and downregulates pathways involved in myogenesis and inflammation. These findings are an important milestone towards clinical translation of treprostinil as an antenatal treatment to prevent pulmonary hypertension in CDH.

CRedT authorship contribution statement

Basurto David: Data curation. Croubels Siska: Formal analysis. Regin Marius: Formal analysis. Partridge Emily: Supervision, Writing – review & editing. Cherlet Marc: Formal analysis. Regin Yannick: Data curation, Formal analysis, Methodology. Russo Francesca Maria: Conceptualization, Data curation, Funding acquisition, Methodology, Resources, Supervision, Writing – review & editing. De Bie Felix Rafael: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Visualization, Writing – original draft, Writing – review & editing. Allegaert Karel: Conceptualization, Methodology, Supervision, Writing – review & editing. Scuglia Marianna: Data curation, Formal analysis. Dubois Antoine: Data curation, Formal analysis, Methodology. Deprest Jan: Conceptualization, Funding acquisition, Investigation, Project administration, Supervision, Writing – review & editing. Muylle Ewout: Data curation, Formal analysis. Arai Tomohiro: Data curation, Formal analysis.

Declaration of Competing Interest

The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.

Data availability

Data will be made available on request.

Acknowledgments

The authors would like to acknowledge Dr. Katrien De Clerq for assisting with placental morphometrical analysis, Dr. Tom Bleeser for assisting with the general anaesthesia procedures, Mrs. Katrien Luyten for histological processing, Ms. Sofie Janes for conducting western blots, Ms. Rita Van Bree for conducting qPCR analysis and Mrs. Inge Bongaerts for assisting with qPCR primer design. Treprostinil was quantified using an UHPLC-MS instrument part of the Ghent University MSsmall Expertise Centre for advanced mass spectrometry analysis of small organic molecules. This work was supported by a grant to the KU Leuven by CDH UK through Sparks (16KUL01). Felix R De Bie was funded by a Strategic Basic Research Grant from the Flanders Research Foundation (FWO – 1S31720N).

Data sharing statement

The authors All data will be made freely available upon written request addressed to the corresponding author. The raw data from our transcriptome analysis was deposited in the GEO repository (GSE220739) and will be accessible online upon publication: https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE220739.

Appendix A. Supporting information

Supplementary data associated with this article can be found in the online version at doi:10.1016/j.biopharm.2023.115996.

References


